Definium Therapeutics, Inc.DFTX

$24.48+0.05 (+0.20%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$3B

Mid-cap

+322701%

2016 — today

10-Year Price

+612%

2016 — today

52-Week Range

$6.49$24.75

Current $24.48· 99%

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Valuation in context

P/E ratio

-9.8

N/A

Not meaningful — company is unprofitable

P/B ratio

9.6

Near historic high

Near historic highs — last 10 years

FCF Yield

-5.4%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when DFTX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.